Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Iloperidone

FDA-approved product (tablet, oral), marketed as Fanapt, Iloperidone.

Registered studies
32
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Iloperidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Iloperidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Iloperidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

    NCT07090161 · start 2025-09-15

    Registered record
    Registry ID
    NCT07090161
    Conditions
    Hypertension; Uncontrolled Hypertension
    Interventions
    iloperidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-15
    Completion
    2026-11
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Uncontrolled Hypertension
    Interventioniloperidone; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Randomized Withdrawal Study in Patients With Schizophrenia

    NCT06961968 · start 2025-05-14

    Registered record
    Registry ID
    NCT06961968
    Conditions
    Schizophrenia
    Interventions
    iloperidone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-14
    Completion
    2027-11
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventioniloperidone; placebo
    PhasePhase 3
    Registry statusRecruiting

  • Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

    NCT06494397 · start 2024-07-11

    Registered record
    Registry ID
    NCT06494397
    Conditions
    Schizophrenia; Bipolar I Disorder
    Interventions
    VHX-896 and iloperidone; Iloperidone and VHX-896
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-11
    Completion
    2024-10-24
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar I Disorder
    InterventionVHX-896 and iloperidone; Iloperidone and VHX-896
    PhasePhase 1
    Registry statusCompleted

  • Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    NCT05648591 · start 2023-05-24

    Registered record
    Registry ID
    NCT05648591
    Conditions
    Schizophrenia; Bipolar I Disorder
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-05-24
    Completion
    2026-11-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Bipolar I Disorder
    InterventionIloperidone
    PhasePhase 4
    Registry statusRecruiting

  • A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

    NCT05344365 · start 2022-06

    Registered record
    Registry ID
    NCT05344365
    Conditions
    Parkinson Disease Psychosis
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-06
    Completion
    2023-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease Psychosis
    InterventionIloperidone
    PhasePhase 2
    Registry statusWithdrawn

  • Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

    NCT04969211 · start 2021-06-30

    Registered record
    Registry ID
    NCT04969211
    Conditions
    Healthy
    Interventions
    VHX-896 and iloperidone; Iloperidone and VHX-896
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2021-10-13
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionVHX-896 and iloperidone; Iloperidone and VHX-896
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

    NCT04819776 · start 2021-03-22

    Registered record
    Registry ID
    NCT04819776
    Conditions
    Bipolar I Disorder
    Interventions
    Iloperidone; Iloperidone Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-03-22
    Completion
    2023-08-16
    Enrolment
    417

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionIloperidone; Iloperidone Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

    NCT04712734 · start 2021-01-13

    Registered record
    Registry ID
    NCT04712734
    Conditions
    Schizophrenia
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2022-08-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionIloperidone
    PhasePhase 1
    Registry statusCompleted

  • Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

    NCT04127058 · start 2019-10-07

    Registered record
    Registry ID
    NCT04127058
    Conditions
    Bipolar I Disorder; Schizophrenia
    Interventions
    Iloperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-10-07
    Completion
    2019-11-27
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder; Schizophrenia
    InterventionIloperidone
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    NCT04002700 · start 2019-05-06

    Registered record
    Registry ID
    NCT04002700
    Conditions
    Stroke
    Interventions
    Haloperidol; Typical Antipsychotics; Atypical Antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-06
    Completion
    2019-05-31
    Enrolment
    1,234,412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke
    InterventionHaloperidol; Typical Antipsychotics; Atypical Antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

    NCT03565068 · start 2018-06-20

    Registered record
    Registry ID
    NCT03565068
    Conditions
    Schizophrenia
    Interventions
    MK-8189; Placebo; Background AAP Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-20
    Completion
    2020-04-03
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionMK-8189; Placebo; Background AAP Therapy
    PhasePhase 1
    Registry statusCompleted

  • A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

    NCT03319953 · start 2017-12-21

    Registered record
    Registry ID
    NCT03319953
    Conditions
    Stable Schizophrenia
    Interventions
    TAK-041; Placebo; Second Generation Antipsychotics (SGA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-12-21
    Completion
    2019-11-06
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStable Schizophrenia
    InterventionTAK-041; Placebo; Second Generation Antipsychotics (SGA)
    PhasePhase 2
    Registry statusCompleted

  • Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets

    NCT03420534 · start 2017-11-17

    Registered record
    Registry ID
    NCT03420534
    Conditions
    Bioequivalence
    Interventions
    Iloperidone 1 MG; Placebo; fasting; postprandial
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2017-11-17
    Completion
    2018-03-14
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionIloperidone 1 MG; Placebo; fasting; postprandial
    PhasePhase 1
    Registry statusUnknown

  • Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    NCT02600741 · start 2015-07-24

    Registered record
    Registry ID
    NCT02600741
    Conditions
    Schizophrenia
    Interventions
    Caregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine; Droperidol; Fluphenazine; Haloperidol; Loxapine; Perphenazine; Pimozide; Prochlorperazine; Thiothixene; Thioridazine; Trifluoperazine; Aripiprazole; Asenapine; Clozapine; Iloperidone; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07-24
    Completion
    2018-07-05
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCaregiver psycho-education and skills training; Caregiver support available at the study site; Paliperidone palmitate; Chlorpromazine +19 more
    PhaseNot recorded
    Registry statusCompleted

  • YouScript IMPACT Registry

    NCT02191358 · start 2014-10

    Registered record
    Registry ID
    NCT02191358
    Conditions
    Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-08
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED +9 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted